Concepedia

Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial

Kara Kliewer, Cristin Murray-Petzold, Margaret H. Collins, J. Pablo Abonia, Scott M. Bolton, Lauren DiTommaso, Lisa J. Martin, Xue Zhang, Vincent A. Mukkada, Philip E. Putnam,

˜The œLancet. Gastroenterology & hepatology · 2023 · 67 citations · 24 references

DOIFull text

Open access

Concepts

References

24

Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-controlled Study

Mario Castro, Sameer K. Mathur, Frederick E. Hargreave et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 718 citations

, , +14

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

Roland Kolbeck, Alexander Kozhich, Masamichi Koike et al. · Journal of Allergy and Clinical Immunology · 2010 · 578 citations · Full text

, , +8

Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial

Jonathan M. Spergel, Marc E. Rothenberg, Margaret H. Collins et al. · Journal of Allergy and Clinical Immunology · 2011 · 551 citations

, , +11

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

Michel Laviolette, David Gossage, Gail M. Gauvreau et al. · Journal of Allergy and Clinical Immunology · 2013 · 508 citations

, , +16

Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis

Evan S. Dellon, Marc E. Rothenberg, Margaret H. Collins et al. · New England Journal of Medicine · 2022 · 456 citations · Full text

, , +17